Alteogen Inc.
196170
Ранг среди акций
#1739
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Цена акции
$174.43
Рыночная капитализация
$12.14B
Изменение (1 день)
5.32%
Изменение (1 год)
-44.70%
Страна
KR
Торговля Alteogen Inc. (196170)
Категория
Healthcare
Коэффициент P/B для Alteogen Inc. (196170)
Коэффициент P/B на October 2026 TTM: 31.65
Согласно последним финансовым отчетам и цене акций Alteogen Inc., текущий коэффициент P/B (TTM) составляет 31.65. В конце 2024 он составлял 60.09.
История P/B для Alteogen Inc. с 2012 по 2026
Коэффициент P/B в конце каждого года
| Год | P/B | Изменить |
|---|---|---|
| 2026 (TTM) | 31.65 | -23.84% |
| 2025 | 41.56 | -30.84% |
| 2024 | 60.09 | 88.28% |
| 2023 | 31.91 | 142.03% |
| 2022 | 13.19 | -53.77% |
| 2021 | 28.52 | -65.29% |
| 2020 | 82.17 | 542.18% |
| 2019 | 12.80 | 118.43% |
| 2018 | 5.86 | -19.72% |
| 2017 | 7.30 | 69.68% |
| 2016 | 4.30 | -28.85% |
| 2015 | 6.04 | 101.09% |
| 2014 | 3.01 | -68.20% |
| 2013 | 9.45 | -27.57% |
| 2012 | 13.05 | 0.00% |
Коэффициент P/B для аналогичных компаний или конкурентов
| Компания | P/B | Разница P/B | Страна |
|---|---|---|---|
| 6.251 | -80.25% |
US
|
|
| 13.2547 | -58.13% |
US
|
|
| 4.4521 | -85.93% |
AU
|
|
| 6.3632 | -79.90% |
NL
|
|
| 3.2932 | -89.60% |
BE
|
